These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34972260)

  • 21. Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study.
    Ismaila AS; Rothnie KJ; Wood RP; Banks VL; Camidge LJ; Czira A; Compton C; Sharma R; Millard SN; Massey O; Halpin DMG
    Respir Res; 2023 Sep; 24(1):229. PubMed ID: 37749551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA.
    Hanania NA; Bunner SH; Bengtson LGS; Ismaila AS; Bogart M
    Int J Chron Obstruct Pulmon Dis; 2023; 18():407-418. PubMed ID: 36998390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life.
    Tabberer M; Lomas DA; Birk R; Brealey N; Zhu CQ; Pascoe S; Locantore N; Lipson DA
    Adv Ther; 2018 Jan; 35(1):56-71. PubMed ID: 29313286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study.
    Nakamura Y; Hozawa S; Sagara H; Ohbayashi H; Lee LA; Crawford J; Tamaoki J; Nishi T; Fowler A
    Curr Med Res Opin; 2021 Sep; 37(9):1657-1665. PubMed ID: 34162298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient and Clinical Demographics of New Users to Single-Inhaler Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease.
    Wu B; Mannino D; Mu G; Stiegler M; Bogart M
    Pulm Ther; 2022 Jun; 8(2):195-208. PubMed ID: 35467260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-World Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol Once-Daily Single-Inhaler Triple Therapy for Symptomatic COPD: The ELLITHE Non-Interventional Trial.
    Beeh KM; Scheithe K; Schmutzler H; Krüger S
    Int J Chron Obstruct Pulmon Dis; 2024; 19():205-216. PubMed ID: 38249826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics of Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol or Other Triple Therapies in Japan: A Real-World Healthcare Claims Database Study (MITOS-AURA).
    Takahashi K; Makita N; Castañeda-Sanabria J; Argoubi R; Nowacki G; Issa S; Matsumoto I; Yoshida Y; Müllerová H
    Adv Ther; 2024 Dec; 41(12):4518-4536. PubMed ID: 39412626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
    Siler TM; Kerwin E; Sousa AR; Donald A; Ali R; Church A
    Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial).
    Zheng J; Zhong N; Wang C; Huang Y; Chen P; Wang L; Hui F; Zhao L; Wang H; Luo L; Du X; Han Goh A; Lipson DA
    COPD; 2018; 15(4):334-340. PubMed ID: 30265816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England.
    Requena G; Czira A; Banks V; Wood R; Tritton T; Castillo C; Yeap J; Wild R; Compton C; Rothnie KJ; Herth FJF; Quint JK; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2023; 18():2039-2054. PubMed ID: 37731774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials.
    Hanania NA; Caveney S; Soule T; Tombs L; Lettis S; Crim C; Mannino DM; Patel H; Boucot IH
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1925-1938. PubMed ID: 34194225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benefit and safety of fluticasone furoate/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups.
    Bakerly ND; Woodcock A; Collier S; Leather DA; New JP; Crawford J; Harvey C; Vestbo J; Boucot I
    Respir Med; 2019 Feb; 147():58-65. PubMed ID: 30704700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial.
    Paly VF; Vallejo-Aparicio LA; Martin A; Izquierdo JL; Riesco JA; Soler-Cataluña JJ; Abreu C; Biswas C; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2022; 17():3097-3109. PubMed ID: 36561129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations.
    Singh D; Criner GJ; Dransfield MT; Halpin DMG; Han MK; Lange P; Lettis S; Lipson DA; Mannino D; Martin N; Martinez FJ; Miller BE; Wise R; Zhu CQ; Lomas D
    Respir Res; 2021 Apr; 22(1):130. PubMed ID: 33910578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.
    Donohue JF; Worsley S; Zhu CQ; Hardaker L; Church A
    Respir Med; 2015 Jul; 109(7):870-81. PubMed ID: 26006754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses.
    Halpin DMG; Birk R; Brealey N; Criner GJ; Dransfield MT; Hilton E; Lomas DA; Zhu CQ; Lipson DA
    ERJ Open Res; 2018 Apr; 4(2):. PubMed ID: 29750142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial.
    Gabrio A; Gunsoy NB; Baio G; Martin A; Paly VF; Risebrough N; Halpin DMG; Singh D; Wise RA; Han MK; Martinez FJ; Criner GJ; Martin N; Lipson DA; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2022; 17():1633-1642. PubMed ID: 35915738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-World Study of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the US.
    Bogart M; Germain G; Laliberté F; Mahendran M; Duh MS; DiRocco K; Noorduyn SG; Paczkowski R; Balkissoon R
    J Asthma Allergy; 2023; 16():1309-1322. PubMed ID: 38058516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis.
    Naya I; Tombs L; Lipson DA; Boucot I; Compton C
    Respir Res; 2019 Mar; 20(1):60. PubMed ID: 30914064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.
    Pascoe S; Barnes N; Brusselle G; Compton C; Criner GJ; Dransfield MT; Halpin DMG; Han MK; Hartley B; Lange P; Lettis S; Lipson DA; Lomas DA; Martinez FJ; Papi A; Roche N; van der Valk RJP; Wise R; Singh D
    Lancet Respir Med; 2019 Sep; 7(9):745-756. PubMed ID: 31281061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.